Trial · NCT00535860
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
NCT00535860, Phase 2, Completed, TransPharma Medical
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis. Trials, record NCT00535860. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00535860
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
- NCT number
- NCT00535860
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 104 participants, actual
- Lead sponsor
- TransPharma Medical
- Conditions
- Osteoporosis
- Interventions
- Teriparatide
- First posted
- 2007-09-26
- Last updated
- 2009-07-10
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline to endpoint 96 days in procollagen 1 N-terminal propeptide (P1NP) | Baseline, 96 days | |
| Secondary | Change from baseline in C-terminal telopeptide of type I collagen (CTX-1.) | Baseline, 96 days | |
| Secondary | hPTH (1-34) Pharmacokinetic AUC of ViaDerm-hPTH (1-34) and teriparatide SC. | Baseline, 96 days | |
| Secondary | Ratio of hPTH (1-34) AUC of transdermal treatment and subcutaneous injection | Baseline, 96 days | |
| Secondary | Ratio of hPTH (1-34) Cmax of transdermal treatment and subcutaneous injection | Baseline, 96 days | |
| Secondary | hPTH (1-34) Pharmacokinetic Cmax of ViaDerm-hPTH (1-34) and teriparatide SC. | Baseline, 96 Days | |
| Secondary | Percentage of patients with serum total calcium above the upper limit of normal range | Over 96 days | |
| Secondary | Percentage of patients with serum total calcium more than 1 mg/dl above the upper limit of normal range | Over 96 days | |
| Secondary | Number of participants with hPTH (1-34) specific antibody immune response | Baseline, 96 days | |
| Secondary | Draize score for erythema and edema | Over 96 Days |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00535860
GET https://conductscience.org/api/trials/v1/NCT00535860/registered